Tafasitamab (Minjuvi®) – Diffuse large B-cell lymphoma (DLBCL), combination with lenalidomide
Characteristics
| Start date | 15.09.2021 |
|---|---|
| Resolution | 03.03.2022 |
| INN | Tafasitamab |
| Brand name | Minjuvi® |
| Pharm. company | Incyte Biosciences Germany |
| G-BA procedure ID | 2021-09-15-D-732 |
| ATC code | L01FX12 |
| ICD-10 codes | C83.3Diffuse large B-cell lymphoma |
| DDD | 60 mg P |
| Therapeutic area | Oncological diseases ORPHAN |
| Reason for procedure | Initial assessment |
| Regulatory status | Conditional Approval |
| Indication (German) |
|---|
|
MINJUVI is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) |
| Subpopulation | Indication | Comparator |
|---|---|---|
| Adults with relapsed or refractory diffuse large B-cell lymphoma (DLCBL), for whom autologous stem cell transplantation (ASCT) is not an option | – (Orphan drug) |
9. Associated procedures
| Resolution | INN | Brand name | Indication | Patients | Additional benefit |
|---|---|---|---|---|---|
| 15.09.2021 – 03.03.2022 | Tafasitamab | Minjuvi® | Diffuse large B-cell lymphoma (DLBCL), combination with lenalidomide | 730 – 1,560 |
<< List of all resolutions